Clinical information
Infections of the respiratory tract are mainly caused by viruses (e. g. SARS-CoV-2, influenza viruses, adenoviruses, RSV), but also by bacteria (e. g. Legionella, Bordetella pertussis, Mycoplasma pneumoniae, Chlamydia pneumoniae). Both the upper (e. g. nasal mucosa, paranasal sinuses) and the lower respiratory tracts (airways and bronchia) can be affected. The pathogens are mainly transmitted by droplet infection. Signs and symptoms of respiratory infections include fever, cough, headache and joint pain, pharyngitis, sinusitis, bronchitis or pneumonia.
Diagnostics
Since many respiratory pathogens cause similar symptoms, the diseases can usually not be diagnosed based on the clinical image alone. Consequently, laboratory diagnostics are particularly valuable. In most cases, direct pathogen detection (e. g. PCR) is the method of choice for the detection of acute respiratory infections. Especially in severe cases and in persons with an increased risk, prompt laboratory diagnostic pathogen detection is indispensable in order to confirm a diagnosis and take suitable measures. In addition to real-time PCR-based assays for fast, precise nucleic acid detection of individual pathogens, multiplex assays allow to test for numerous pathogens in a single sample in order to determine whether an infection is present and which pathogen is causing it.
Because antibodies are not produced until days or weeks after infection, and because the prevalence increases with age, infection can often only be diagnosed retrospectively by examining a pair of serum samples and detecting the increase in the IgG titer. Serological tests can also contribute to epidemiological surveillance.
| Technology | Parameter | Substrate | Species | Calibration | Ig Class | Format | Order No. |
|---|---|---|---|---|---|---|---|
| ELISA |
Anti-MERS-CoV ELISA (IgG) Middle east respiratory syndrome coronavirus |
antigen-coated microplate wells |
recombinant S1 antigen of MERS coronavirus (MERS-CoV S1) |
semi-quantitative | IgG |
96 x 01 |
EI 2604-9601 G |
| ELISA |
Anti-SARS-CoV-2 ELISA (IgA) Severe acute respiratory syndrome coronavirus 2 |
antigen-coated microplate wells |
recombinant S1 antigen of SARS-CoV-2 |
semi-quantitative | IgA |
96 x 01 |
EI 2606-9601 A |
| ELISA |
Anti-SARS-CoV-2 ELISA (IgG) Severe acute respiratory syndrome coronavirus 2 |
antigen-coated microplate wells |
recombinant S1 antigen of SARS-CoV-2 |
semi-quantitative | IgG |
96 x 01 |
EI 2606-9601 G |
| ELISA |
Anti-SARS-CoV-2 QuantiVac ELISA (IgG) Severe acute respiratory syndrome coronavirus 2 |
1/10/20/40/80/120 RU/mL | IgG |
96 x 01 |
EI 2606-9601-10 G | ||
| ELISA |
Anti-SARS-CoV-2 NCP ELISA (IgG) Severe acute respiratory syndrome coronavirus 2 nucleocapsid protein |
semi-quantitative | IgG |
96 x 01 |
EI 2606-9601-2 G | ||
| ChLIA | Anti-SARS-CoV-2 RBD ChLIA (IgG) | Antigen-coated magnetic particles | quantitative | IgG |
100 x 1 |
LI 2606-10010-1 G | |
| ChLIA | Control set Anti-SARS-CoV-2 RBD ChLIA (IgG) | 2 x 0.5 ml control 1/2 | IgG |
02 x 02 |
LR 2606-20210-1 G | ||
| ELISA | Anti-Adenovirus ELISA (IgA) |
antigen-coated microplate wells |
native antigens from Adenovirus |
semi-quantitative | IgA |
96 x 01 |
EI 2680-9601 A |
| ELISA | Anti-Adenovirus ELISA (IgG) |
antigen-coated microplate wells |
native antigens from Adenovirus |
2/20/200 RU/ml | IgG |
96 x 01 |
EI 2680-9601 G |
| ELISA | Anti-Adenovirus ELISA (IgM) |
antigen-coated microplate wells |
native antigens from Adenovirus |
semi-quantitative | IgM |
96 x 01 |
EI 2680-9601 M |
| ELISA | Anti-Chlamydia trachomatis Advanced ELISA (IgA) | semi-quantitative | IgA |
96 x 01 |
EI 2191-9601-1 A | ||
| ELISA | Anti-Chlamydia trachomatis Advanced ELISA (IgG) | quantitative | IgG |
96 x 01 |
EI 2191-9601-1 G | ||
| IIFT |
Legionella Mosaic 8 Legionella pneumophila mixture 5 Legionella longbeachae |
3 BIOCHIPs per field: bacterial smear bacterial smear verification BIOCHIP |
L. pneumophila L. longbeachae |
IgAGM |
10 x 05 |
FI 2150-1005-8 P | |
| IIFT |
Legionella pneumophila serotype 1 |
bacterial smear verification BIOCHIP (2 BIOCHIPs per field) |
Legionella pneumophila |
IgAGM IgAGM |
10 x 05 10 x 10 |
FI 2151-1005 P FI 2151-1010 P |
|
| IIFT |
Legionella pneumophila mixture 5 (serotype 1 - 7) |
bacterial smear functional BIOCHIP |
Legionella pneumophila | IgAGM IgAGM |
10 x 05 10 x 10 |
FI 215k-1005-1 P FI 215k-1010-1 P |
|
| ELISA | Anti-Legionella pneumophila ELISA (IgG) |
antigen-coated microplate wells |
suspension of Legionella pneumophila serotypes 1-7 |
2/20/200 RU/ml | IgG |
96 x 01 |
EI 2150-9601 G |
| ELISA | Anti-Legionella pneumophila ELISA (IgM) |
antigen-coated microplate wells |
suspension of Legionella pneumophila serotypes 1-7 |
semi-quantitative | IgM |
96 x 01 |
EI 2150-9601 M |
| ELISA | Anti-Mycoplasma pneumoniae ELISA (IgA) |
antigen-coated microplate wells |
detergent extract from Mycoplasma pneumoniae |
semi-quantitative | IgA |
96 x 01 |
EI 2202-9601 A |
| ELISA | Anti-Mycoplasma pneumoniae ELISA (IgG) |
antigen-coated microplate wells |
detergent extract from Mycoplasma pneumoniae |
2/20/200 RU/ml | IgG |
96 x 01 |
EI 2202-9601 G |
| ELISA | Anti-Mycoplasma pneumoniae ELISA (IgM) |
antigen-coated microplate wells |
detergent extract from Mycoplasma pneumoniae |
semi-quantitative | IgM |
96 x 01 |
EI 2202-9601 M |
| ELISA |
Anti-RSV ELISA (IgA) Respiratory syncytial virus |
antigen-coated microplate wells |
native antigens from RSV |
semi-quantitative | IgA |
96 x 01 |
EI 2670-9601 A |
| ELISA |
Anti-RSV ELISA (IgG) Respiratory syncytial virus |
antigen-coated microplate wells |
native antigens from RSV |
2/20/200 RU/ml | IgG |
96 x 01 |
EI 2670-9601 G |
| ELISA |
Anti-RSV ELISA (IgM) Respiratory syncytial virus |
antigen-coated microplate wells |
native antigens from RSV |
semi-quantitative | IgM |
96 x 01 |
EI 2670-9601 M |
| ELISA |
Anti-Parainfluenza Viruses Pool ELISA (IgA) (Pool) |
antigen-coated microplate wells |
native antigens from Parainfluenza virus types 1 - 4 |
semi-quantitative | IgA |
96 x 01 |
EI 2721-9601-1 A |
| ELISA |
Anti-Parainfluenza Viruses Pool ELISA (IgG) (Pool) |
antigen-coated microplate wells |
native antigens from Parainfluenza virus types 1 - 4 |
2/20/200 RU/ml | IgG |
96 x 01 |
EI 2721-9601-1 G |
| ELISA | Anti-Bordetella pertussis toxin ELISA (IgA) |
antigen-coated microplate wells |
natives Bordetella pertussis toxin |
2/10/25/50 IU/ml | IgA |
96 x 01 |
EI 2050-9601 A |
| ELISA | Anti-Bordetella pertussis toxin ELISA (IgG) |
antigen-coated microplate wells |
natives Bordetella pertussis toxin |
5/25/100/200 IU/ml | IgG |
96 x 01 |
EI 2050-9601 G |
| ELISA | Anti-Bordetella pertussis ELISA (IgM) |
antigen-coated microplate wells |
inactivated Bordetella pertussis lysate |
semi-quantitative | IgM |
96 x 01 |
EI 2050-9601 M |
| ELISA | Anti-Bordetella FHA ELISA (IgA) |
antigen-coated microplate wells |
native Bordetella pertussis filamentous haemagglutinin |
2/10/25/50 IU/ml | IgA |
96 x 01 |
EI 2050-9601-3 A |
| ELISA | Anti-Bordetella FHA ELISA (IgG) |
antigen-coated microplate wells |
native Bordetella pertussis filamentous haemagglutinin |
5/25/100/200 IU/ml | IgG |
96 x 01 |
EI 2050-9601-3 G |
| ELISA | Anti-Influenza A Virus ELISA (IgA) |
antigen-coated microplate wells |
strains "Texas" (H3N2), "California" (H1N1) and "Singapore" (H1N1) |
semi-quantitative | IgA |
96 x 01 |
EI 2691-9601 A |
| ELISA | Anti-Influenza A Virus ELISA (IgG) |
antigen-coated microplate wells |
strains "Texas" (H3N2), "California" (H1N1) and "Singapore" (H1N1) |
2/20/200 RU/ml | IgG |
96 x 01 |
EI 2691-9601 G |
| ELISA | Anti-Influenza B Virus ELISA (IgA) |
antigen-coated microplate wells |
strain"Hong Kong 5/72" | semi-quantitative | IgA |
96 x 01 |
EI 2692-9601 A |
| ELISA | Anti-Influenza B Virus ELISA (IgG) |
antigen-coated microplate wells |
strain"Hong Kong 5/72" | 2/20/200 RU/ml | IgG |
96 x 01 |
EI 2692-9601 G |
| EUROLINE |
positive control serum: IgA, human, 50x concentrated for Bordetella pertussis |
IgA |
05 x 07 |
CL 2050-0507 A | |||
| EUROLINE |
positive control serum: IgG, human, 50x concentrated for Bordetella pertussis |
IgG |
05 x 07 |
CL 2050-0507 G | |||
| EUROLINE |
EUROLINE Bordetella pertussis (IgA) (FHA, PT, ACT separately) |
EUROLINE | IgA IgA |
16 x 01 240 x 01 |
DN 2050-1601 A DN 2050-24001 A |
||
| EUROLINE |
EUROLINE Bordetella pertussis (IgG) (FHA, PT, ACT separately) |
EUROLINE | IgG IgG |
16 x 01 240 x 01 |
DN 2050-1601 G DN 2050-24001 G |
||
|
* For research use only, not for in vitro diagnostic use in the sense of EU directive 98/79/EC. 1 Product manufactured by third party. Please contact your local Euroimmun representative for more information. | |||||||